Zobrazeno 1 - 10
of 435
pro vyhledávání: '"immunocytokine"'
Autor:
Patrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, Laetitia Petersen, Nicole Egli, Simone Popp, Catherine Regnier, Kirsten Richter, Andreas Katopodis, Christoph Huber
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivity toward effector over regulatory T cells and reducing dose-limiting toxicities. Here we describe ANV419, an IL-2/anti-IL2 an
Externí odkaz:
https://doaj.org/article/c58320a3176c45a68cbb1b5dbf7c8122
Autor:
Arezoo Beig Parikhani, Rada Dehghan, Yeganeh Talebkhan, Elham Bayat, Alireza Biglari, Mohammad Ali Shokrgozar, Reza Ahangari Cohan, Esmat Mirabzadeh, Soheila Ajdary, Mahdi Behdani
Publikováno v:
AMB Express, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The immunotherapeutic application of interleukin-2 (IL-2) in cancer treatment is limited by its off-target effects on different cell populations and insufficient activation of anti-tumor effector cells at the site of the tumor upon tolerated
Externí odkaz:
https://doaj.org/article/ef08f57dd2e34293b7ae0942d1f63137
Publikováno v:
Biomolecules, Vol 14, Iss 11, p 1399 (2024)
Monoclonal antibodies (mAbs) are widely used in cancer therapy but often show limited efficacy for solid tumors. Enhancing anti-tumor activity by fusing cytokines to tumor-targeting mAbs, which specifically activate immune cells within the tumor micr
Externí odkaz:
https://doaj.org/article/4b8c2679e6ee4da29119a3015d185635
Autor:
Louis Plüss, Frederik Peissert, Abdullah Elsayed, Giulia Rotta, Jonas Römer, Sheila Dakhel Plaza, Alessandra Villa, Emanuele Puca, Roberto De Luca, Annette Oxenius, Dario Neri
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTThere are no effective treatment options for most patients with metastatic colorectal cancer (mCRC). mCRC remains a leading cause of tumor-related death, with a five-year survival rate of only 15%, highlighting the urgent need for novel pharm
Externí odkaz:
https://doaj.org/article/b2b1ebf228944e2ba4c6dcab246edd47
Autor:
Noah Tsarovsky, Mildred Felder, Mackenzie Heck, Jacob Slowinski, Kayla Rasmussen, Sabrina VandenHeuvel, Jen Zaborek, Zachary S. Morris, Amy K. Erbe, Paul M. Sondel, Alexander L. Rakhmilevich
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionWe have previously shown that an intratumoral (IT) injection of the hu14.18-IL2 immunocytokine (IC), an anti-GD2 antibody linked to interleukin 2, can serve as an in situ vaccine and synergize with local radiotherapy (RT) to induce T cell
Externí odkaz:
https://doaj.org/article/31fc084eb860409982966059be52b354
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Cytokines are pivotal mediators of cell communication in the tumor microenvironment. Multiple cytokines are involved in the host antitumor response, but the production and function of these cytokines are usually dysregulated during malignant tumor pr
Externí odkaz:
https://doaj.org/article/f5a2dd278c0647fc812caba0679b1191
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sun-Hee Kim, Hee-Jin Jeong
Publikováno v:
Current Issues in Molecular Biology, Vol 44, Iss 1, Pp 301-308 (2022)
Immunocytokines, antibody-cytokine fusion proteins, have the potential to improve the therapeutic index of cytokines by delivering the cytokine to the site of localized tumor cells using antibodies. In this study, we produced a recombinant anti-progr
Externí odkaz:
https://doaj.org/article/9f9a3339dea64f7b83d17e7d678e4083
Autor:
Ana Victoria Casadesús, Beatriz María Cruz, Wilden Díaz, Miguel Ángel González, Tania Gómez, Briandy Fernández, Addys González, Nuris Ledón, Katya Sosa, Kathleen Castro, Armando López, Claudia Plasencia, Yaima Ramírez, Jean-Luc Teillaud, Calixto Hernández, Kalet León, Tays Hernández
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionThe anti-CD20 antibody rituximab (RTX) has substantially improved outcomes of patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing lymphomas. An approach to increase the clinical effecti
Externí odkaz:
https://doaj.org/article/27dd8b21477249bb9be6a6d8cabd48c2